Rev Med reports out on the 46% of the pancreatic cancer patients who were enrolled in NCT05379985 (54% of patients are NSLC or other cancer).
The slides present info on those patients that are KRAS G12X (e.g. G12V, G12R). They also report out "RAS Mutant" defined as patients with G12X, G13X or Q61X PDAC
“The webcast will take place at 8:00 a.m. Eastern Time on Monday, July 15, 2024. To access the live webcast, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the event.”
SLIDES (some are posted below)
A Phase 3 trial “RASolute is planned for the 2nd half of 2024
POSTS ABOUT RMC-6236 in this group:
PRELIMINARY RESULTS FOR PHASE 1 TRIAL
NCT05379985
Feb 2023)
ESMO conference - October 2023 pre-clinical results
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
REVOLUTION MEDICINE scientific presentation ESMO23
New trial NCT06445062 (opened May 2024)
Phase 1/2 trial - 406 PATIENTS
In April, 2024 Dr. Salman Punekar, Pan-Ras Trials at the KRAS KICKERS 2024 Hope Filled Summit (discussion 19 -25 minutes)
Comments